BLUE bluebird bio, Inc.

78.70
-1.10  -1%
Previous Close 79.80
Open 79.75
Price To book 4.01
Market Cap 3.22B
Shares 40,950,000
Volume 583,501
Short Ratio 8.80
Av. Daily Volume 689,931

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2017.
LentiGlobin - HGB-212
TDT and the β0/β0genotype
Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017. Updated data at ASCO June 5, 2017. Abstract 3010
bb2121
Relapsed/refractory multiple myeloma
Noted on December 14, 2016 that Phase 3 dosing has commenced. Early data due at EHA June 25, 2017.
LentiGlobin - HGB-207 Northstar-2
non-β0/β0 transfusion-dependent thalassemia (TDT)
Phase 2/3 trial initiated October 2013. Interim data released at AAN Conference April 20, 2016. Full data due by the end of 2017.
Lenti-D - Starbeam
Childhood cerebral adrenoleukodystrophy (CCALD)
Updated data presented at ASH December 5, 2016.
LentiGlobin - HGB-204
β-Thalassemia
Update at ASH 2016. Further data due at ASH 2017. Exact date TBC.
LentiGlobin - HGB-206
Sickle disease

Latest News

  1. bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : May 23, 2017
  2. bluebird bio Announces Collaboration with Duke University’s Robert J. Margolis, MD, Center for Health Policy on Value-Based Payment Framework for Gene Therapy
  3. ETFs with exposure to bluebird bio, Inc. : May 22, 2017
  4. bluebird bio to Present New Data from LentiGlobinTM Clinical Studies at European Hematology Association (EHA) Annual Meeting
  5. Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting
  6. bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting
  7. bluebird bio Updates, Investors Wait
  8. bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
  9. Bluebird reports 1Q loss
  10. bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress
  11. Cambridge's bluebird bio licenses delivery tech to Novartis, GSK
  12. bluebird bio Enters Lentiviral Vector Patent License Agreement with GlaxoSmithKline for Commercialization of Gene Therapies
  13. bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies
  14. Better Buy: Ionis Pharmaceuticals, Inc. vs. bluebird bio
  15. bluebird bio to Present at Upcoming Investor Conferences
  16. bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : April 26, 2017
  17. 3 Things You Didn't Know About bluebird bio, Inc.
  18. bluebird bio, Inc. – Value Analysis (NASDAQ:BLUE) : April 17, 2017